Abstracts

Expand All

2019


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL,


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


• Arts KE, Kato D, Dancey J. Establishment of a baseline to measure academic clinical trial activity in Canada. J Clin Oncol 33[suppl; abstr e17547].


- Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[suppl; abstr e17710].


- Penniment MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[(suppl 3; abstr 6)]. 2015.


- Ramjeesingh R, Kankesan J, Chen BE, Pater JL, Han L, O'Brien P, Burnell MJ, Shepherd LE, Parulekar WR. Clinical predictors of failure of granulocyte colony...
stimulating factor (G-CSF) prophylaxis in patients with breast cancer treated with dose dense epirubicin (E), cyclophosphomide (C) + paclitaxel (T) Adjuvant chemotherapy: Subgroup analysis of the NCIC CTG MA.21 study (NCT00014222). J Clin Oncol 33[suppl; abstr 1033].


- Lohmann AE, Chapman J-AW, Burnell MJ, Levine MN, Tsvetkova E, Pritchard KI,


cyclophosphamide followed by Paclitaxel (AC/T) in a randomized trial (RCT), compared to a case-control matched British Columbia (BC) breast cancer population. J Clin Oncol 32:5s[suppl; abstr 1037]. 2014.


2013

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

Lymphoproliferative Disorders, 2013.


- Moy B, Tu D, Richardson H, Maunsell E, Goss PE. NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. J Clin Oncol 31[ suppl; abstr 6557], 2013.


- Renouf DJ, Parulekar W, Grigorieva J, Tu D, Moore MJ. Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. J Clin Oncol 31[ suppl; abstr 4061], 2013.

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2012

BIG-NABCG investigators. Quantitative hormone receptors, triple negative breast cancer (TNBC), and molecular subtypes: a collaborative effort of the BIG-NCI NABCG. J Clin Oncol 30[suppl, abstr 1008], 2012.

German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone. Blood (ASH Annual Meeting Abstracts) 120[21, abstr 548], 2012.


- Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[suppl, abstr 524], 2012.


• Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer M, Jefford M, Magoski NM, Haydon A, Walters I, Tu D, O'Callaghan CJ, on behalf of NCIC CTG and AGITG. Final Analysis of the Phase III randomized trial of cetuximab (CET) + either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. J Clin Oncol 30[suppl, abstr 3504], 2012


• Steele R, Quirke P, Grieve R, Monson J, Couture J, de Metz C, Pugh C, Nichols L, Thompson LC, Sebag-Montefiore D, on behalf of all investigators MCTUL. Long Term Outcome After Anastomotic Leak and the Impact of Short Course Pre-Operative Radiotherapy - Data from the MRC CRO7 NCIC CO16 trial. 6th European Multidisciplinary Colorectal Cancer Congress, 2012.


concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6). J Clin Oncol 30[suppl, abstr TPS5600], 2012.


---

**2011**


- Basik M, Keilty D, Aleynikova O, Tu D, Li X, Shepherd LE, Bramwell V. Measurement of Pax2, TC21,CCND1, and RFS1 as predictive biomarkers for outcomes in the NCIC CTG


- Dong B, Chapman J-AW, Yerushalmi R, Goss PE, Pollak MN, Burnell MJ, Bramwell VH,


- Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.


2010


- Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28[18s, abstr CRA3507], 2010.

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.


Oncol 28[15s, abstr 3090], 2010.


- Macdonald DA, Assouline SE, Brandwein J, Kamel-Reid S, Eisenhauer EA, Couban S, Foo A, Leber B. Phase I/II study of low-dose cytarabine with sorafenib as first-line...


Verleye L, Ottevanger PB, Amant F, Kristensen GB, van der Burg MEL, Verheijen R,


2009


• Cheang M, Chia SK, Tu D, Jiang S, Shepherd LE, Pritchard KI, Nielsen TO. Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol 27[15s], 2009.


• Craddock KJ, Buys TPH, Zhu CQ, Strumpf D, Pintillie M, Ding K, Seymour L, Jurisica I, Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals regions of DNA copy number gain that may be predictive of benefit from adjuvant chemotherapy. J Thoracic Oncol 4[9 suppl 1, abstr PD12.2.6], S580. 2009.


Symposium, 2009.


- Laurie SA, Arnold A, Shepherd FA, Dediu M, Ciuleanu T, Fenton D, Zukin M, Goss G,
Ding K, Seymour L. Overall survival results of NCIC Clinical Trials Group BR.24: A randomized, double-blind trial of carboplatin + paclitaxel with either daily oral cediranib, a potent inhibitor of all vascular endothelial growth factor receptor tyrosine ki. J Thoracic Oncol 4[9 suppl 1, abstr C1.1], S353. 2009.


- Strevel EL, Ding K, Seymour L, Tsao MS, Le Maître A, Shepherd FA, Burkes RL.


2008


- Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.


2007


- Au H-J, Brundage M, Ringash J, Bezjak A, Palmer M, Richardson H, Lee CW, Maunsell E, Brotho L, Sussman J, Davis A, Osoba D. Added value of health-related quality of life outcomes in NCIC CTG clinical trials: results from QOL committee workshop. Quality of


• Chapman JW, Meng D, Shepherd L, Parulekar W, Ingle J, Muss H, Palmer M, Yu C,


- Parker C, Sydes MR, Catton C, Kynaston H, Logue J, Morash C, Payne H, Murphy C, Parulekar W, Savage C, Clarke NW. RADICALS - an Intergroup randomised controlled trial in prostate cancer of radiotherapy timing and hormone therapy duration after radical prostatectomy (MRC PR10, NCIC PR13, ISRCTN40814031). NCRI United Kingdom,
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

2007.

- Tsao MS, Lau S, Boutros P, Pintilie M, Zhu C-Q, Strumpf D, Penn L, Jurisica I, Shepherd FA. Gene expression prognostic classifiers for early stage non-small cell lung


- Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.


2006


• Goldberg RM, McLeod HL, Sargent DJ, Morton RF, Green EM, Fuchs C, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. Genetic polymorphisms, toxicity,
and response rate in African Americans (AA) with metastatic colorectal cancer (MCRC) compared to Caucasians (C) when treated with IFL, FOLFOX or IROX in Intergroup N9741. J Clin Oncol 24[18S Part 1, abstr 3503]. 2006.


- O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrushis I, Pritchard KI. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1], S18, 2006.


• Pater JL, Tu D, Ingle JN, Shepherd LE, Goss PE. An evaluation of the early termination of MA.17 extended adjuvant therapy trial. Breast Cancer Treatment and Research 100[Suppl 1], S107, 2006.


• Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], S59, 2005.
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

- Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.
- Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.
- Seymour L, Goss G. Epidermal growth factor receptor tyrosine kinase inhibitors: is dose


- Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.


2004


- Chi K, Eisenhauer E, Fazli L, Jones EC, Powers J, Ayers D, Goldenberg SL, Gleave


- Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.


- Goss P, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione MM, Tu D,


- Paridaens R, Therasse P, Dirix L, Beex L, Piccart M, Cameron D, Cifer T, Roozendaal


Mazumdar M, Tu D. Efficiency of STRTA matched case-control studies with multiple controls per case in survival data setting. Controlled Clin Trials 24(3S), 112S, 2003.


Clin Cancer Res 9(suppl), 6094s, 2003.


2002


man dose escalation and pharmacokinetic study of the novel nucleoside analog

Grilli C, Shepherd F, Perrone F, Illiano A, Plantedosi F, Robbiati S, Manzoni L,
Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Findlay B, Hirsh V, Seymour L,
Bezjak A, Gallo C. GEMVIN III: A phase III study of gemcitabine plus vinorelbine
compared to cisplatin plus vinorelbine or gemcitabine chemotherapy for stage IIIb or IV
292a, 2002.

Hamilton M, Wolf J, Demetri G, Seiden M, de Vries E, Eisenhauer E, Gelmon K,
Hammond A, Rovinsky E, Hirte H, Rothenberg M, Verweij J, Sparreboom A, Versluis J,
Cumbertson J, Roberts L, Ptaszynski M, Santabarbara P. Phase I pharmacokinetics of
21(part 1), 90a, 2002.

Hayter C, Lukka H. Process and outcome of real-time radiotherapy review in a national
study of prostate cancer radiotherapy. Int.J.Rad.Oncol.Biol.Phys. 54[2(suppl 1)], 276,
2002.

Hirte H, Siu L, Gelmon K, Britten C, Eisenhauer E, Fisher B, Ptaszynski M, Oneatto N.
Phase I study of NX211/cisplatin given as an intravenous infusion on days 1, 2 & 3
every 3 weeks in patients with solid cancer - an NCIC Clinical Trials Group study.

Eisenhauer E. A phase II study of T138067-sodium in patients with malignant glioma. A

Lopez AB, Ridderheim M, Havesten H, Scheistroen M, Eisenhauer E. First line
treatment of ovarian cancer FIGO stage Iib-IV with paclitaxel/epirubicin/carboplatin
versus paclitaxel/carboplatin. Interim results of an NSGO-EORTC-NCIC CTG
202a, 2002.

Kwok A, Zee B. Group sequential design for a global tests statistic with mixed endpoints.
Controlled Clin.Trials 23(2S), 94s, 2002.

Langer B, Bleiberg H, Labianca R, Shepherd L, Nitti D, Marsoni S, Tu D, Sargeant A,
Fields A. Fluorouracil plus l-leucovorin versus observation after potentially curative
resection of liver or lung metastases from colorectal cancer: results of the ENG
(EORTC/NCIC CTG/GIVIO) randomized trial. Proc.Am.Soc.Clin.Oncol. 21(part 1), 149a,
2002.

Liu J, Tu D, Pater J. A comparative analysis of quality of life data from a clinical trial in

MacDonald S, Dudgeon DJ, Bruea E, Gagnon B, Watanabe S, Allan S, Warr D, Savage
C, Pater J. A phase III double-blind equivalence study of two different formulations of
slow-release morphine followed by a randomization between dextromethorphan or
placebo plus statex SR for chronic cancer pain relief in terminally ill patients.

Madarnas Y, Fine S, Sawka C, Shepherd L, Tannock I, Tu D, Levine M. Body size,
received dose-intensity and myelotoxicity of adjuvant chemotherapy in relation to
outcome of premenopausal women with N1 breast cancer: results from a NCIC Clinical


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2001


Parulekar W, Trudeau M, Shepherd L, Ottaway J, Day A, Franssen E, Bramwell V,


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2000


- Oza A, Eisenhauer E, Swenerton K, Elit L, Ghatage P, Carey M, Faught W, McIntosh L,

- Walker H, Stuart G, Bacon M, Eisenhauer E, Bacon E, Tu D, Zee B. Comparative cost-


1999

- Geels P, Eisenhauer E, Bezjak A, Zee B, Day A. The palliative effect of chemotherapy in


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

1998

- Gertler SZ, Macdonald D, Goodyear M, Forsyth P, Stewart DJ, Seymour L, Wainman N.


- Pater J, Bezjak A, Osoba D, Zee B, Palmer M. Quality of life as an endpoint in NCIC Clinical Trials Group studies: Have we learned anything new? Ann.Oncol. 9(suppl 4),


Zhao F, Tu D, Pater J. Bootstrap variable selection and model validation for a Cox's
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1997


• Tu D. Statistical procedures in therapeutic equivalence clinical trials with ordered


1996


- Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.


**1995**


- Latreille J, Johnston D, Laberge F, Stewart D, Rusthoven J, Nishimura L, Pater J, Zee B. Use of granisetron and dexamethasone on day 2-7 following high dose cisplatin.


- Lofters C, Zee B. Adding 5 HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.


- Lofters W, Zee B. Adding 5HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 339, 1995.


Supportive Care in Cancer 3(5), 344, 1995.


1994


- Zee B, James K, Johnston D. Design and analysis of late randomization trials: information from time to first response in multiple myeloma. Joint ASA and Biometric
1993


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogenous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.
- Zee B. One-sided test for clinical trials with group sequential design that allow early
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1991


304, 1990.


1989


- Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin.Trials 10(3), 351, 1989.

1988


1987

1986

- Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.

1985
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1984

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1983


1981